HER2-Targeted Therapies for Metastatic Breast Cancer Watch our June 2024 MBC Impact Series, Metastatic HER2-Positive Breast Cancer. HER2 and metastatic breast cancer The HER2 protein is an important driver of cell growth and survival. A pathologist determines HER2 status by testing a sample of the metastatic tumor (from a biopsy of the metastases). Learn more […]| Susan G. Komen®
Invasive Lobular Breast Cancer Watch our Mission Moment webinar, Invasive Lobular Breast Cancer. Read our fact sheet on invasive lobular breast cancer. What is invasive lobular breast cancer? Invasive lobular cancer or infiltrating lobular carcinoma (ILC) is invasive breast cancer that begins in the lobules of the breast. The lobules are small, round sacs in […]| Susan G. Komen®
CDK4/6 Inhibitors for Metastatic Breast Cancer CDK4 and CDK6 are enzymes important in cell division. CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells. CDK4/6 inhibitors are used in combination with hormone therapy to treat some hormone receptor-positive breast cancers. The CDK4/6 inhibitors FDA-approved for metastatic breast cancer treatment are: Drug name […]| Susan G. Komen®
Hormone Therapy for Metastatic Breast Cancer Watch Susan G. Komen®’s January 2024 MBC Impact Series, Metastatic Breast Cancer and Estrogen Receptor-Positive Breast Cancer. What is hormone therapy? Estrogen and progesterone are female hormones produced in the body. Some breast cancer cells need estrogen and/or progesterone to grow. When these hormones attach to special proteins called […]| Susan G. Komen®
Learn how hormone therapies can slow or stop the growth of hormone receptor-positive breast cancer tumors by preventing the cancer cells from getting the hormones they need to grow.| Susan G. Komen®
Learn about ethylene oxide, which can raise your risk of lymphoma and leukemia. Exposure may occur through industrial emissions, tobacco smoke, and the use of products sterilized with ethylene oxide, such as certain medical products or cosmetics.| www.cancer.gov
